Description: Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Home Page: www.cellectis.com
8, rue de la Croix Jarry
Paris,
75013
France
Phone:
33 1 81 69 16 00
Officers
| Name | Title |
|---|---|
| Dr. Andre Choulika Ph.D. | Co-Founder, CEO & Director |
| Dr. David J. D. Sourdive Ph.D. | Director, Deputy CEO, Exec. VP of CMC and Manufacturing |
| Dr. Bing C. Wang M.B.A., Ph.D. | Chief Financial Officer |
| Valerie Cros | Principal Financial Officer & Principal Accounting Officer |
| Mr. Jean Charles Epinat | Chief Technological Officer |
| Dr. Philippe Duchateau Ph.D. | Chief Scientific Officer |
| Mr. Stephan Reynier M.Sc., MSc | Chief Regulatory & Pharmaceutical Compliance Officer |
| Ms. Marie-Bleuenn Terrier | Gen. Counsel & Sec. of the Board of Directors |
| Pascalyne Wilson | Director of Communications |
| Ms. Kyung Nam-Wortman | Exec. VP & Chief HR Officer |
Exchange: PA
Country: FR
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7696 |
| Price-to-Sales TTM: | 4.3384 |
| IPO Date: | 2007-02-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 294 |